{
 "PrintNo":"S8193","Session":2021,"Chamber":"SENATE","BillType":"Senate","Published":"2022-02-01T12:47:52.19009Z",
 "Status":"IN_SENATE_COMM","Committee":"Insurance",
 "Milestones":[{"Type":"IN_SENATE_COMM","Date":"2022-02-01","Committee":"Insurance"}],
 "Actions":[{"Text":"REFERRED TO INSURANCE","Date":"2022-02-01","Chamber":"SENATE"}],
 "Sponsors":[{"ID":372,"Name":"Neil D. Breslin","Short":"BRESLIN"},{"ID":1101,"Name":"John E. Brooks","Short":"BROOKS"}],
 "Title":"Relates to the applicability of step therapy to certain medically necessary prescription drugs",
 "Summary":"Ensures that step therapy shall not apply to medically necessary prescription drugs in the dermatologic, hematology, ophthalmologic, rheumatic, gastrointestinal, neurology, and oncology therapeutic classes, including non-formulary drugs.",
 "LawSection":"Insurance Law","LawCode":"Amd ยง4902, Ins L; amd ยง4902, Pub Health L",
 "ActClause":"AN ACT to amend the insurance law and the public health law, in relation to protecting certain therapeutic classes from step therapy",
 "SameAsPrintNo":"A9250-2021"
}